Pharmaceutical Investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Pharmaceutical Investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
West High Yield Resources Receives Green-Light Permit for Record Ridge Industrial Mineral Mine - Advancing Canada's Domestic Critical Mineral Refining
